Clinical trials: Streptococcus Infection
Pneumococcal Infections
13-valent Pneumococcal Conjugate Vaccine Study in Adults => 50 Years of Age in Mexico
The purpose of this study will be to assess the safety, tolerability, and immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) when given to healthy adults older than 50 years of age who haven't received 23-valent…
- Trial name
- NCT01432262
- Testing
- vaccine-13vPnC
- Where
- 4 sites in Mexico
- Volunteers
- 324 people, healthy volunteers welcome
- Sponsor
- Pfizer
Infections, Streptococcal
Post Marketing Surveillance of Synflorix Vaccine Safety Among Infants in Korea
The purpose of this study is to collect safety information following routine vaccination with Synflorix™ among infants in Korea.
- Trial name
- NCT01248988
- Testing
- Synflorix™ Data collection
- Where
- South Korea
- Volunteers
- 622 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Dengue, Chikungunya
Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective
RACSMEI addresses the high burden of infectious diseases in low- and middle-income countries, including Cambodia, where limited surveillance and laboratory capacity often obscure etiologies and transmission dynamics.
- Conditions
- Dengue, Chikungunya, Zika Virus Infection, Japanese Encephalitis
- Trial name
- RACSMEI (NCT07358910)
- Where
- Cambodia
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur du Cambodge
Infections, Streptococcal
Primary Vaccination Course in Children Receiving the Pneumococcal Vaccine GSK 1024850A, Zilbrix™ Hib and Polio Sabin™
The purpose of this study is to assess the immunogenicity in terms of antibody response and the safety/reactogenicity in terms of solicited and unsolicited symptoms and serious adverse events following primary vaccination of…
- Trial name
- NCT00678301
- Testing
- GSK Biologicals' Synflorix™, GSK Biologicals' Polio Sabin™, GSK Biologicals' Zilbrix™ Hib
- Where
- 2 sites in Mali, Nigeria
- Volunteers
- 365 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Microbial Colonization
Probiotic Toothpaste for Microbial Colonization
The aim of this study is to evaluate the colonization efficacy of probiotic toothpastes in healthy adults
- Trial name
- NCT05480020
- Testing
- Streptococcus salivarius M18 toothpaste
- Where
- New Zealand
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- John Hale
Pneumonia, Pneumococcal
Immunogenicity and Safety Study of 15-Valent Pneumococcal Conjugate Vaccine in 2-month-old and 3-month-old Healthy Volunteers
The purpose of this study is to evaluate Immunogenicity and safety of 15-Valent Pneumococcal Conjugate Vaccine in healthy volunteers aged 2 and 3 months.
- Trial name
- NCT04357522
- Testing
- 15-Valent Pneumococcal Conjugate Vaccine, 13-Valent Pneumococcal Conjugate Vaccine
- Where
- 3 sites in China
- Volunteers
- 1,950 people, healthy volunteers welcome
- Sponsor
- Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd
Pneumococcal Infections
Pneumococcal Conjugate Vaccine With Pneumococcal Polysaccharide Vaccine and Tetanus/Diphtheria Vaccine
The purpose of this study is to learn whether or not giving a tetanus/diphtheria vaccination ("tetanus shot") before giving pneumococcal vaccine makes the pneumococcal vaccine more effective without causing too many side effects.
- Trial name
- NCT00164411
- Testing
- Tetanus-diphtheria toxoids (Td), 7-valent pneumococcal conjugate vaccine, 23-valent polysaccharide vaccine
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Centers for Disease Control and Prevention
Pneumonia, Pneumococcal, Pneumonia Childhood
Paediatric Pneumococcal Pneumonia in Malaysia Prior to and During Pneumococcal Conjugate Vaccine (PCV) Implementation
The purpose of this research is to provide baseline surveillance of pneumonia in young children in Malaysia before and during the implementation of the pneumococcal conjugate vaccine (PCV).
- Trial name
- MSIP PCV (NCT04923035)
- Where
- 3 sites in Malaysia
- Volunteers
- 1,010 people, healthy volunteers welcome
- Sponsor
- IMU University, Malaysia
Pneumococcal Infections, Meningococcal Infections
Response of United Kingdom (UK) Infants to a Reduced Primary Schedule With Meningococcal C and Pneumococcal Conjugate Vaccines
The purpose of the study is to evaluate the immune responses of UK infants after one or two doses of pneumococcal conjugate vaccine or one or two doses of three different types of meningococcal conjugate vaccine given at either…
- Trial name
- sched1 (NCT00197808)
- Testing
- menjugate, Men C conjugate vaccine, Men C conjugate
- Where
- 2 sites in United Kingdom
- Volunteers
- 392 people, healthy volunteers welcome
- Sponsor
- Public Health England
Pneumococcal Disease
A Study to Assess the Impact of Pneumococcal Conjugate Vaccination Programme on the Carriage of Pneumococci
A study taking swabs from the back of the nose (nasopharynx) to look at carriage of pneumococci.
- Trial name
- Pneucast (NCT01040143)
- Where
- 3 sites in United Kingdom
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- Public Health England
Pneumococcal Disease
Safety Surveillance of Pneumococcal 13-valent Conjugate Vaccine Among Filipinos
Prevenar 13 is safe for administration to Filipinos.
- Trial name
- NCT01396434
- Testing
- Prevenar 13
- Where
- 119 sites in Philippines
- Volunteers
- 3,006 people, healthy volunteers welcome
- Sponsor
- Pfizer
Pneumococcal Infections
Immunogenicity and Safety Study of NBP606 in Healthy Toddlers
This study will assess the immunogenicity and safety of booster vaccination with NBP606 compared to the existing commercial vaccine, when given concomitantly with routine pediatric vaccinations.
- Trial name
- NCT02927444
- Testing
- NBP606, Prevnar13
- Where
- South Korea
- Volunteers
- 462 people, healthy volunteers welcome
- Sponsor
- SK Chemicals Co., Ltd.
Bacterial Infection Due to Streptococcus, Group B, Streptococcus Agalactiae
Extension Study to Evaluate the Immunogenicity and Safety of the Second Dose of GBS Trivalent Vaccine in Healthy Non-Pregnant Subjects.
The objective of this extension study is the initial assessment of safety and immunogenicity of the second dose of GBS Trivalent Vaccine following the time interval that is close to the inter-pregnancy interval observed in the…
- Trial name
- NCT02690181
- Testing
- GBS Trivalent Vaccine
- Where
- Belgium
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Streptococcus Group A
Rheumatic Heart Disease Prevalence in Leon, Nicaragua
A bacterium called Group A Steptoccoccus or "strep" is commonly found in the nose and throat of healthy adults and children and can cause a variety of illnesses.
- Trial name
- NCT00307112
- Where
- Nicaragua
- Volunteers
- 2,193 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Pneumococcal Infections
Evaluation of the Safety and Immunogenicity of Sequential Administration of Prevnar 13™ and Pneumovax™ 23 in Healthy Participants 50 Years of Age and Older (V110-029)
The purpose of this study is to evaluate the safety and immunogenicity of sequential administration of Prevnar 13™ and Pneumovax™ 23 in healthy participants 50 years of age and older.
- Trial name
- NCT02225587
- Testing
- Prevnar 13™, Pneumovax™ 23
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Group B Streptococcal Infections
Study to Evaluate the Safety, Tolerability and Immunogenicity of Three Doses of GBS Vaccine in Elderly Participants
The study is a randomised, double-blind, placebo-controlled, parallel group study to evaluate the safety, tolerability and immunogenicity of three doses of GBS NN/NN2 with Alhydrogel® (Recombinant protein vaccine against Group B…
- Trial name
- NCT05782179
- Testing
- GBS-NN/NN2
- Where
- Belgium
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Minervax ApS
Pneumococcal Disease
A Study to Learn About a Type of Pneumococcal Vaccine With a New Ingredient (PF-07872411) Intended to Enhance the Effects of the Vaccine Which is Given to Adults
The purpose of this clinical trial is to learn about a pneumococcal vaccine with a new ingredient (PF-07872411) intended to enhance the effects of the vaccine.
- Trial name
- NCT05831124
- Testing
- Low dose multivalent pneumococcal conjugate vaccine formulation A, Low dose multivalent pneumococcal conjugate vaccine formulation B, Low dose of multivalent pneumococcal conjugate vaccine control
- Where
- 9 sites in United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Pfizer
Pneumococcal Infectious Disease
Clinical Trial of PCV24 in Infants Aged 2-23 Months
A Phase 1b clinical trial of 24-valent pneumococcal conjugate vaccine (PCV24) developed by Sinovac Life Science Co., Ltd will be conducted in pediatric population aged 2 months (minimum 42 days)-23 months.
- Trial name
- NCT06800261
- Testing
- Sinovac PCV24, Prevnar®
- Where
- 2 sites in China
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Sinovac Life Sciences Co., Ltd.
Pneumococcal Disease
Safety and Immunogenicity of V114 in Healthy Infants in South Korea (V114-036)
The primary purpose of this phase 3, single-arm, open-label study is to evaluate the safety and immunogenicity of a 4-dose regimen of V114 administered to healthy infants in South Korea.
- Trial name
- PNEU-PED-KOR (NCT04633226)
- Testing
- V114
- Where
- 19 sites in South Korea
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Pneumococcal Infection
Safety, Tolerability, and Immunogenicity of V110 or V114 Co-administered With a Booster Dose of mRNA-1273 in Healthy Adults (V110-911)
The purpose of this study is to evaluate the concomitant and non-concomitant use of messenger ribonucleic acid (mRNA) mRNA-1273, the nucleoside-modified mRNA vaccine for active immunization to prevent coronavirus disease…
- Trial name
- NCT05158140
- Testing
- V110, V114, mRNA-1273
- Where
- 46 sites in United States, Puerto Rico
- Volunteers
- 850 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC